Sign in

    Edward Nash • Canaccord Genuity

    Edward Nash's questions to Corcept Therapeutics Inc (CORT) leadership

    Edward Nash's questions to Corcept Therapeutics Inc (CORT) leadership • Q2 2025

    Question

    Speaking for Edward Nash of Canaccord Genuity, Xinwei asked about relacorilant's positioning in ovarian cancer, physician sentiment on its use in early vs. late-stage disease, and potential overlapping toxicities in future combination therapies.

    Answer

    Roberto Vieira, President of Oncology, outlined a path to market leadership in platinum-resistant ovarian cancer, projecting over $1 billion in long-term revenue, supported by flexible use across therapy lines. He and CEO Joseph Belanoff noted strong physician interest for use in earlier lines due to the drug's efficacy and safety. Chief Development Officer William Guyer stated there are no concerns about overlapping toxicities with other agents.

    Ask Fintool Equity Research AI

    Edward Nash's questions to Corcept Therapeutics Inc (CORT) leadership • Q1 2025

    Question

    Edward Nash asked about the oncology program, specifically the treatment paradigm for relacorilant versus competitors like Elahere and any feedback from oncologists on the ROSELLA data. He also inquired about the revenue cadence for the remainder of the year, questioning if a large bolus should be expected in Q2 following the resolution of pharmacy issues.

    Answer

    Roberto Vieira, President of the Oncology division, explained that relacorilant plus nab-paclitaxel is positioned to become a new standard of care in platinum-resistant ovarian cancer and can be used before or after biomarker-driven agents. Sean Maduck, President of the Endocrinology division, and CEO Joseph K. Belanoff clarified that they do not expect a single revenue bolus in Q2, but rather accelerating growth throughout the rest of the year.

    Ask Fintool Equity Research AI